๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Topotecan

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 28 trials in our China, USA, UK, Ireland and India registers that name Topotecan as an intervention. Synced 24 Sep 2026
28Trials tracked
17Recruiting now
23Lead sponsors
5Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Topotecan is named as a drug or biological intervention in 28 clinical trials in our China, USA, UK, Ireland and India trial registers, 17 of which are recruiting. Lead sponsors include Eli Lilly and Company (2), Daiichi Sankyo (2) and Genmab (2). Registered phases: Phase 3, Phase 1, Phase 2, Phase 2/3, Phase 1/2 and Phase EARLY_PHASE1. Conditions studied include Epithelial Ovarian Cancer; Ovarian Cancer; Small Cell Lung Cancer.

01

Clinical trials of Topotecan

28 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT06972602 High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed (ClinicalTrials.gov ↗)
Retinoblastoma, Retinoblastoma, Recurrent
 Phase EARLY_PHASE1 Recruiting Eye & ENT Hospital of Fudan University China
NCT04799002 Topotecan and Melphalan for Retinoblastoma (ClinicalTrials.gov ↗)
Retinoblastoma, Chemotherapy Effect
 Phase 3 Recruiting Sun Yat-sen University China
NCT06203210 A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Small Cell Lung Cancer
 Phase 3 Recruiting Daiichi Sankyo USA, China
NCT06394492 SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer (ClinicalTrials.gov ↗)
Ovarian Cancer
 Phase 3 Recruiting Suzhou Suncadia Biopharmaceuticals Co., Ltd. China
NCT06498479 ARTEMIS-008๏ผšHS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Small Cell Lung Cancer
 Phase 3 Recruiting Hansoh BioMedical R&D Company China
NCT06801834 Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
 Phase 3 Recruiting Gilead Sciences UK, USA, China
NCT06855069 HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer (ClinicalTrials.gov ↗)
Ovarian Cancer
 Phase 3 Recruiting Hansoh BioMedical R&D Company China
NCT06954246 A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Small Cell Lung Cancer Extensive Stage
 Phase 3 Recruiting Qilu Pharmaceutical Co., Ltd. China
NCT06994195 A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) (ClinicalTrials.gov ↗)
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
 Phase 3 Recruiting Sichuan Baili Pharmaceutical Co., Ltd. China
NCT07099898 A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Neoplasms, Lung
 Phase 3 Recruiting GlaxoSmithKline Ireland, UK, USA
NCT07213804 A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
 Phase 3 Recruiting Eli Lilly and Company Ireland, UK, USA, China
NCT07218809 AZD5335 vs. Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 vs. Chemotherapy in FRฮฑ-low Platinum-resistant Ovarian Cancer
Epithelial Ovarian Cancer
 Phase 3 Recruiting AstraZeneca Ireland, UK, USA, India, China
NCT07365241 A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Small Cell Lung Cancer
 Phase 3 Recruiting AbbVie USA
NCT07604766 An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China (ClinicalTrials.gov ↗)
Platinum-resistant Ovarian Cancer
 Phase 3 Recruiting Genmab China
NCT06161025 A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (ClinicalTrials.gov ↗)
Solid Cancer
 Phase 2/3 Recruiting Daiichi Sankyo UK, USA, China
NCT05652686 A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) (ClinicalTrials.gov ↗)
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC)
 Phase 1/2 Recruiting Phanes Therapeutics USA
NCT06930755 Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Ovarian Cancer
 Phase 1 Recruiting Nerviano Medical Sciences USA
NCT07545460 A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer (ClinicalTrials.gov ↗)
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
 Phase 3 Not yet open Sichuan Baili Pharmaceutical Co., Ltd. China
NCT07797153 JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer (ClinicalTrials.gov ↗)
Recurrent or Metastatic Cervical Cancer
 Phase 3 Not yet open Jiangsu Alphamab Biopharmaceuticals Co., Ltd China
NCT05303727 Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma (ClinicalTrials.gov ↗)
Neuroblastoma
 Phase 2 Not yet open Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University China
NCT05740566 Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Small Cell Lung Cancer (SCLC)
 Phase 3 Active, closed Amgen Ireland, UK, USA, China
NCT06459180 A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Cervical Cancer
 Phase 3 Active, closed Merck Sharp & Dohme LLC Ireland, UK, USA, China
NCT06616532 PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer (ClinicalTrials.gov ↗)
SCLC
 Phase 3 Active, closed Biotheus Inc. China
NCT06619236 Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (ClinicalTrials.gov ↗)
Platinum-resistant Ovarian Cancer
 Phase 3 Active, closed Genmab USA, China
NCT03709680 Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors (ClinicalTrials.gov ↗)
Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor
 Phase 2 Active, closed Pfizer UK, USA, India
NCT06449209 Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy (ClinicalTrials.gov ↗)
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
 Phase 2 Active, closed BioNTech SE UK, USA
NCT04106219 A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Neuroblastoma
 Phase 1 Active, closed Eli Lilly and Company UK, USA
NCT05990738 DAREONโ„ข-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy (ClinicalTrials.gov ↗)
Small Cell Lung Carcinoma (SCLC)
 Phase 1 Active, closed Boehringer Ingelheim UK, USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

32 conditions
Condition (as registered)Trials
Epithelial Ovarian Cancer3
Ovarian Cancer3
Small Cell Lung Cancer3
Small Cell Lung Cancer (SCLC)2
Neuroblastoma2
Platinum-resistant Ovarian Cancer2
Retinoblastoma2
Fallopian Tube Cancer2
Primary Peritoneal Cancer2
Ovarian Neoplasms1
Fallopian Tube Neoplasms1
Peritoneal Neoplasms1
Neoplasm Metastasis1
Neoplasms, Lung1
Cervical Cancer1
Solid Cancer1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)1
Extensive-stage Small-cell Lung Cancer1
Small-cell Lung Cancer1
Ewing Sarcoma1
Solid Tumors1
Rhabdoid Tumor1
Rhabdomyosarcoma1
Small Cell Lung Carcinoma (SCLC)1
Large Cell Neuroendocrine Cancer (LCNEC)1
Neuroendocrine Prostate Cancer (NEPC)1
Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)1
Recurrent or Metastatic Cervical Cancer1
Retinoblastoma, Recurrent1
SCLC1
Small Cell Lung Cancer Extensive Stage1
Chemotherapy Effect1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Eli Lilly and Company2
Daiichi Sankyo2
Genmab2
Sichuan Baili Pharmaceutical Co., Ltd.2
Hansoh BioMedical R&D Company2
AstraZeneca1
GlaxoSmithKline1
Merck Sharp & Dohme LLC1
Amgen1
Gilead Sciences1
BioNTech SE1
Pfizer1
Boehringer Ingelheim1
Nerviano Medical Sciences1
AbbVie1
Phanes Therapeutics1
Jiangsu Alphamab Biopharmaceuticals Co., Ltd1
Eye & ENT Hospital of Fudan University1
Biotheus Inc.1
Qilu Pharmaceutical Co., Ltd.1
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
Sun Yat-sen University1
Suzhou Suncadia Biopharmaceuticals Co., Ltd.1
04

Trials by country register

RegisterTopotecan trials
Clinical trials in China20
Clinical trials in USA16
Clinical trials in UK11
Clinical trials in Ireland5
Clinical trials in India2

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Topotecan works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Topotecan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.